Schering submits MS-325 for EU approval

German pharmaceutical firm Schering has submitted Epix Medical 's MS-325 intravenous blood pool MR angiography contrast agent for marketing approval in the European Union.

MS-325, co-developed by Cambridge, MA-based Epix and Schering of Berlin, is designed specifically for vascular imaging in patients receiving MRA, according to the firms. The agent was submitted for U.S. marketing clearance in December 2003. By AuntMinnie.com staff writers
June 7, 2004

Related Reading

Epix raises $96 million, June 4, 2004

Epix floats new debt, June 2, 2004

Schering gets Swedish approval for Primovist, April 5, 2004

Schering gets European OK for Zevalin for NHL, January 22, 2004

Epix, Schering to partner on MRI contrast, May 27, 2003

Copyright © 2004 AuntMinnie.com

Page 1 of 606
Next Page